Federal Register / Vol. 89, No. 207 / Friday, October 25, 2024 / Notices 85215 

Jeffrey M. Zirger, 

Lead, Information Collection Review Office, 

Office of Scientific Integrity, Office of Science, 

Centers for Disease Control and Prevention. 

[FR Doc. 2024–24921 Filed 10–24–24; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

[60Day–25–1385; Docket No. CDC–2024– 

0084] 

Proposed Data Collection Submitted 

for Public Comment and 

Recommendations 

AGENCY: Centers for Disease Control and 

Prevention (CDC), Department of Health 

and Human Services (HHS). 

ACTION: Notice with comment period. 

SUMMARY: The Centers for Disease 

Control and Prevention (CDC), as part of 

its continuing effort to reduce public 

burden and maximize the utility of 

government information, invites the 

general public and other federal 

agencies the opportunity to comment on 

a continuing information collection, as 

required by the Paperwork Reduction 

Act of 1995. This notice invites 

comment on a proposed information 

collection project titled Characteristics 

of Cases of Priority Fungal Diseases. 

These case report forms (CRF) collect 

information on patient demographics, 

underlying conditions, diagnosis, 

treatments, healthcare utilization, and 

outcomes of patients with 

coccidioidomycosis, histoplasmosis, 

blastomycosis, Candida auris, triazoleresistant Aspergillus fumigatus infection 

or colonization, or antifungal-resistant 

dermatophytosis, chromoblastomycosis, 

mycetoma, and sporotrichosis. 

DATES: CDC must receive written 

comments on or before December 24, 

2024. 

ADDRESSES: You may submit comments, 

identified by Docket No. CDC–2024– 

0084 by either of the following methods: 

• Federal eRulemaking Portal: 

www.regulations.gov. Follow the 

instructions for submitting comments. 

• Mail: Jeffrey M. Zirger, Information 

Collection Review Office, Centers for 

Disease Control and Prevention, 1600 

Clifton Road NE, MS H21–8, Atlanta, 

Georgia 30329. 

Instructions: All submissions received 

must include the agency name and 

Docket Number. CDC will post, without 

change, all relevant comments to 

www.regulations.gov. 

Please note: Submit all comments 

through the Federal eRulemaking portal 

(www.regulations.gov) or by U.S. mail to 

the address listed above. 

FOR FURTHER INFORMATION CONTACT: To 

request more information on the 

proposed project or to obtain a copy of 

the information collection plan and 

instruments, contact Jeffrey M. Zirger, 

Information Collection Review Office, 

Centers for Disease Control and 

Prevention, 1600 Clifton Road NE, MS 

H21–8, Atlanta, Georgia 30329; 

Telephone: 404–639–7570; Email: omb@

cdc.gov. 

SUPPLEMENTARY INFORMATION: Under the 

Paperwork Reduction Act of 1995 (PRA) 

(44 U.S.C. 3501–3520), federal agencies 

must obtain approval from the Office of 

Management and Budget (OMB) for each 

collection of information they conduct 

or sponsor. In addition, the PRA also 

requires federal agencies to provide a 

60-day notice in the Federal Register 

concerning each proposed collection of 

information, including each new 

proposed collection, each proposed 

extension of existing collection of 

information, and each reinstatement of 

previously approved information 

collection before submitting the 

collection to the OMB for approval. To 

comply with this requirement, we are 

publishing this notice of a proposed 

data collection as described below. 

The OMB is particularly interested in 

comments that will help: 

1. Evaluate whether the proposed 

collection of information is necessary 

for the proper performance of the 

functions of the agency, including 

whether the information will have 

practical utility; 

2. Evaluate the accuracy of the 

agency’s estimate of the burden of the 

proposed collection of information, 

including the validity of the 

methodology and assumptions used; 

3. Enhance the quality, utility, and 

clarity of the information to be 

collected; 

4. Minimize the burden of the 

collection of information on those who 

are to respond, including through the 

use of appropriate automated, 

electronic, mechanical, or other 

technological collection techniques or 

other forms of information technology, 

e.g., permitting electronic submissions 

of responses; and 

5. Assess information collection costs. 

Proposed Project 

Characteristics of Cases of Priority 

Fungal Diseases (OMB Control No. 

0920–1385, Exp. 4/30/2027)— 

Revision—National Center for Emerging 

and Zoonotic Infectious Diseases 

(NCEZID), Centers for Disease Control 

and Prevention (CDC). 

Background and Brief Description 

Fungal diseases cause substantial 

illness, ranging from mild infection to 

severe or life-threatening invasive 

disease. They also constitute a 

considerable financial burden on 

patients and healthcare systems. 

Awareness of fungal diseases is low, 

and data collection has historically been 

limited in size, scope, and coordination, 

which has hindered our understanding 

of these diseases. Detailed 

epidemiologic and clinical data are 

critical to inform appropriate public 

health responses. 

CDC plans to enhance surveillance of 

high priority fungal diseases across the 

United States to better characterize 

factors such as disease burden, 

geographic scope, patient risk factors, 

health disparities, healthcare utilization, 

outcomes, and emerging trends. This 

project will serve as a Revision to the 

information collection project 

Characteristics of Cases of Priority 

Fungal Diseases (OMB Control No. 

0920–1385). The Revision will expand 

the number of fungal diseases for which 

data may be collected. In addition to 

triazole-resistant A. fumigatus 

infections, coccidioidomycosis, 

histoplasmosis, blastomycosis, C. auris, 

and antifungal-resistant 

dermatophytosis, Case Report Forms 

(CRF) have also been developed for 

chromoblastomycosis, mycetoma, and 

sporotrichosis. 

CDC plans to use standardized CRFs 

to collect public health surveillance 

data for cases of these diseases regarding 

demographics (e.g., age, sex, race/ 

ethnicity, location of residence), 

underlying medical conditions, 

diagnosis (e.g., clinical presentation, 

laboratory testing), treatments, and 

outcomes (e.g., hospitalization, vital 

status). The corresponding CRF would 

be filled out voluntarily by state, local 

or tribal health departments, federal 

agencies, and members of the private 

sector (e.g., academic institutions), and 

contains a section for medical chart 

review and an optional supplemental 

interview (including data on potential 

occupational or environmental 

exposures) of the patient or their 

representative. Findings can help 

identify populations at higher risk of 

these diseases, detect emerging 

epidemiologic trends, and guide 

prevention and response efforts. They 

can also help better focus public and 

healthcare provider outreach, inform 

efforts to contain or mitigate spread, and 

influence health policy and research on 

prevention and treatment. 


ddrumheller on DSK120RN23PROD with NOTICES1
85216 Federal Register / Vol. 89, No. 207 / Friday, October 25, 2024 / Notices 

CDC requests OMB approval for an 

estimated 1,564 annual burden hours. 

There is no cost to respondents other 

than their time to participate. 

ESTIMATED ANNUALIZED BURDEN HOURS

Form name Type of respondent Number of 

respondents 

Number 

responses per 

respondent 

Avg. burden 

per 

response 

(in hrs.) 

Total 

burden 

(in hrs.) 

Triazole-resistant Aspergillus fumigatus Case Report Form State and Local Health Departments .... 15 15 0.5 113 

Coccidioidomycosis Case Report Form ................................ State and Local Health Departments .... 10 25 1.0 250 

Private Sectors ...................................... 3 10 1.0 30 

Histoplasmosis Case Report Form ....................................... State and Local Health Departments .... 10 25 1.0 250 

Private Sectors ...................................... 3 10 1.0 30 

Blastomycosis Case Report Form ........................................ State and Local Health Departments .... 10 25 1.0 250 

Private Sectors ...................................... 3 10 1.0 30 

Candida auris Case Report Form ......................................... State and Local Health Departments .... 15 20 0.75 225 

Private Sectors ...................................... 3 10 0.75 23 

Antifungal-resistant dermatophytosis case report form ........ State and Local Health Departments .... 10 10 0.5 50 

Chromoblastomycosis case report form ............................... Private Sectors ...................................... 25 10 0.5 125 

Mycetoma case report form .................................................. Private Sectors ...................................... 25 5 0.5 63 

Sporotrichosis case report form ............................................ Private Sectors ...................................... 25 10 0.5 125 

Total ............................................................................... ............................................................... ...................... .......................... .................... 1,564 

Jeffrey M. Zirger, 

Lead, Information Collection Review Office, 

Office of Public Health Ethics and 

Regulations, Office of Science, Centers for 

Disease Control and Prevention. 

[FR Doc. 2024–24922 Filed 10–24–24; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Meeting of the Lead Exposure and 

Prevention Advisory Committee 

AGENCY: Centers for Disease Control and 

Prevention (CDC), Department of Health 

and Human Services (HHS). 

ACTION: Notice of meeting. 

SUMMARY: In accordance with the 

Federal Advisory Committee Act, the 

Centers for Disease Control and 

Prevention announces the following 

meeting for the Lead Exposure and 

Prevention Advisory Committee 

(LEPAC). This virtual meeting is open to 

the public. Advance registration by 

December 4, 2024, is needed to receive 

the information to join the meeting. The 

registration link is provided in the 

addresses section below. 

DATES: The meeting will be held on 

December 11, 2024 from 11 a.m. to 5 

p.m., EST. 

ADDRESSES: Register in advance https:// 

events.gcc.teams.microsoft.com/event/ 

0e538aa3-bc82-43e9-89ee-d997b498c

fe6@9ce70869-60db-44fd-abe8-d27670

77fc8f to receive information to join the 

meeting. 

FOR FURTHER INFORMATION CONTACT: Paul 

Allwood, Ph.D., M.P.H., Designated 

Federal Officer, National Center for 

Environmental Health, Centers for 

Disease Control and Prevention, 4770 

Buford Highway, Atlanta, Georgia 

30341, Telephone: 770–488–6774; 

Email: LEPAC@cdc.gov. 

SUPPLEMENTARY INFORMATION: 

Background: The Lead Exposure and 

Prevention Advisory Committee was 

established under Section 2203 of 

Public Law 114–322, the Water 

Infrastructure Improvements for the 

Nation Act; 42 U.S.C. 300j–21, Registry 

for Lead Exposure and Prevention 

Advisory Committee. 

Purpose: The LEPAC is charged with 

providing advice and guidance to the 

Secretary, Department of Health and 

Human Services (HHS), and the 

Director, CDC and Administrator, 

ATSDR, on (1) reviewing Federal 

programs and services available to 

individual communities exposed to 

lead; (2) reviewing current research on 

lead exposure to identify additional 

research needs; (3) reviewing and 

identifying best practices, or the need 

for best practices regarding lead 

screening and the prevention of lead 

poisoning; (4) identifying effective 

services, including services relating to 

healthcare, education, and nutrition for 

individuals and communities affected 

by lead exposure and lead poisoning, 

including in consultation with, as 

appropriate, the lead exposure registry 

as established in Section 2203(b) of 

Public Law 114–322; and (5) 

undertaking any other review or 

activities that the Secretary determines 

to be appropriate. 

Matters to be Considered: The agenda 

will include presentations and 

discussions on the following topics: 

vote on the 2023 annual LEPAC report, 

report from the Preventing Lead 

Exposure in Adults workgroup, lead 

related updates from the LEPAC 

members, local perspective on 

improving blood lead testing, blood lead 

testing strategies. Agenda items are 

subject to change as priorities dictate. 

Public Participation 

Oral Public Comment: The public 

comment period is scheduled on 

December 11, 2024, from 12:30 p.m. 

until 12:50 p.m., EST. Individuals 

wishing to make a comment during the 

public comment period, please email 

your name, organization, and phone 

number by November 25, 2024, to 

LEPAC@cdc.gov. 

The Director, Office of Strategic 

Business Initiatives, Office of the Chief 

Operating Officer, Centers for Disease 

Control and Prevention, has been 

delegated the authority to sign Federal 

Register notices pertaining to 

announcements of meetings and other 

committee management activities, for 

both the Centers for Disease Control and 

Prevention and the Agency for Toxic 

Substances and Disease Registry. 

Kalwant Smagh, 

Director, Office of Strategic Business 

Initiatives, Office of the Chief Operating 

Officer, Centers for Disease Control and 

Prevention. 

[FR Doc. 2024–24925 Filed 10–24–24; 8:45 am] 

BILLING CODE 4163–18–P 


ddrumheller on DSK120RN23PROD with NOTICES1